84 related articles for article (PubMed ID: 15769796)
1. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
van der Hoek J; Waaijers M; van Koetsveld PM; Sprij-Mooij D; Feelders RA; Schmid HA; Schoeffter P; Hoyer D; Cervia D; Taylor JE; Culler MD; Lamberts SW; Hofland LJ
Am J Physiol Endocrinol Metab; 2005 Aug; 289(2):E278-87. PubMed ID: 15769796
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the deubiquitinase gene USP8 cause Cushing's disease.
Reincke M; Sbiera S; Hayakawa A; Theodoropoulou M; Osswald A; Beuschlein F; Meitinger T; Mizuno-Yamasaki E; Kawaguchi K; Saeki Y; Tanaka K; Wieland T; Graf E; Saeger W; Ronchi CL; Allolio B; Buchfelder M; Strom TM; Fassnacht M; Komada M
Nat Genet; 2015 Jan; 47(1):31-8. PubMed ID: 25485838
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
5. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
6. Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer.
Treppiedi D; Catalano R; Mangili F; Mantovani G; Peverelli E
Endocr Oncol; 2022 Jan; 2(1):R143-R152. PubMed ID: 37435454
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations.
Peverelli E; Treppiedi D; Mantovani G
Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.
Gentilin E; Borges De Souza P; Ambrosio MR; Bondanelli M; Gagliardi I; Zatelli MC
J Endocrinol Invest; 2023 Dec; 46(12):2609-2616. PubMed ID: 37233978
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide treatment in Cushing's disease: A single tertiary center's experience.
Şahin S; Karimova G; Özcan ŞG; Durcan E; Özkaya HM; Kadıoğlu P
Turk J Med Sci; 2022 Apr; 52(2):467-476. PubMed ID: 36161631
[TBL] [Abstract][Full Text] [Related]
10. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.
Treppiedi D; Marra G; Di Muro G; Esposito E; Barbieri AM; Catalano R; Mangili F; Bravi F; Locatelli M; Lania AG; Ferrante E; Indirli R; Nozza E; Arlati F; Spada A; Arosio M; Mantovani G; Peverelli E
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626057
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
12. Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.
Tauchmanova L; Breitschaft A; Holder G; Han KT; Choudhury S; Darstein C; Paul M; Drutinus E; Gericke G; Schmid HA; Pedroncelli AM
Endocrine; 2022 Feb; 75(2):537-548. PubMed ID: 34741720
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.
Peverelli E; Treppiedi D; Mangili F; Catalano R; Spada A; Mantovani G
Nat Rev Endocrinol; 2021 Sep; 17(9):560-571. PubMed ID: 34194011
[TBL] [Abstract][Full Text] [Related]
14. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors.
Castellnou S; Vasiljevic A; Lapras V; Raverot V; Alix E; Borson-Chazot F; Jouanneau E; Raverot G; Lasolle H
Endocr Connect; 2020 Feb; 9(3):243-53. PubMed ID: 32101529
[TBL] [Abstract][Full Text] [Related]
15. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.
Gatto F; Barbieri F; Arvigo M; Thellung S; Amarù J; Albertelli M; Ferone D; Florio T
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412614
[TBL] [Abstract][Full Text] [Related]
16. The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas.
Lu M; Wang Y; Zhan X
Front Endocrinol (Lausanne); 2019; 10():330. PubMed ID: 31231308
[TBL] [Abstract][Full Text] [Related]
17. The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".
Pivonello R; Arnaldi G; Scaroni C; Giordano C; Cannavò S; Iacuaniello D; Trementino L; Zilio M; Guarnotta V; Albani A; Cozzolino A; Michetti G; Boscaro M; Colao A
Endocrine; 2019 Jun; 64(3):657-672. PubMed ID: 30968338
[TBL] [Abstract][Full Text] [Related]
18. High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma.
Behling F; Honegger J; Skardelly M; Gepfner-Tuma I; Tabatabai G; Tatagiba M; Schittenhelm J
Int J Endocrinol; 2018; 2018():1763735. PubMed ID: 30627156
[TBL] [Abstract][Full Text] [Related]
19. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.
Vukomanovic VR; Matovic M; Doknic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Peulic M; Djukic A
Nucl Med Commun; 2019 Jan; 40(1):41-51. PubMed ID: 30334858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
